Skip to content

Rif S El-Mallakh

4 papers in the library · 43 citations · publishing 2007-2026

Papers

Sort Most recent Most cited

Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.

Journal of psychopharmacology (Oxford, England) February 5, 2026 Benjamin R. Lewis, Matthew J Reid, Andrew M Novick et al.

Classical psychedelics-a broad class of compounds that include psilocybin, lysergic acid diethylamide, dimethyltryptamine, and mescaline-have shown significant promise for the treatment of mental health conditions in recent clinical trials. Organizations such as the National Network of Depression Centers (NNDCs) can play a pivotal role in uniting researchers and clinicians working in this field...

High Baseline Plasma Anthranilic Acid Predicts Remission Upon Acute-Series Ketamine Infusion for Treatment-Resistant Depression.

Biological Psychiatry Global Open Science July 1, 2025 Stephen A Murata, Zachary B Madaj, Colt D Capan et al. 1 citation

Treatment-resistant depression (TRD) remains a challenge, but intravenous racemic ketamine offers rapid antidepressant effects. Reliable biomarkers are needed. In this study, we examined kynurenine pathway metabolites and inflammatory cytokines as predictors of ketamine response. The Bio-K study was a multicenter, open-label trial of 74 patients with TRD who received 3 ketamine infusions over...

Effects of somatic treatments on suicidal ideation and completed suicides

Brain and Behavior November 25, 2021 Elise M Hawkins, William Coryell, Stephen Leung et al. 25 citations

Abstract Objective This work was undertaken to define and characterize the role of currently available somatic treatments in psychiatry in either increasing or reducing the risk for suicide. Methods Members of the Suicide Prevention Task Group of the National Network of Depression Centers performed a literature review of somatic treatments known to increase or reduce the risk for suicide. The...

MDMA (Ecstasy)

Annals of Clinical Psychiatry 2007 Rif S El-Mallakh, Henry David Abraham 17 citations

BACKGROUND: 3,4-Methylenedioxymethamphetamine (MDMA or Ecstasy) is a synthetic amphetamine analogue that is recreationally used to obtain a psychological effect of enhanced affiliative emotional response. Its use in Western countries appears to be increasing, particularly among young individuals. METHODS: Pertinent basic and clinical literature is critically reviewed. RESULTS: A significant...